LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Inicio・Lista de Acciones・Incyte Corp

Incyte Corp

Cerrado

SectorSanidad

97.03 -0.48

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

96.92

Máximo

97.38

Métricas clave
By Trading Economics
Ingresos	4.1M 303M
Ventas	-234M 1.3B
P/B Media del Sector	13.445 49.701
BPA	1.81
Margen de beneficios	23.834
Empleados	2,844
EBITDA	-47M 367M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+11.46% upside

Dividendos
By Dow Jones
Próximas Ganancias	28 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-31M 19B
Apertura anterior	97.51
Cierre anterior	97.03

Noticias sobre sentimiento de mercado

By Acuity

25%

75%

47 / 345 Clasificación en Healthcare

Incyte Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

22 may 2026, 16:33 UTC

Ganancias

Principales Movimientos del Mercado

Webull Shares Slide on 1Q Loss, Soaring Costs

22 may 2026, 21:10 UTC

Ganancias

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 may 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

22 may 2026, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

22 may 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

22 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

22 may 2026, 19:47 UTC

Ganancias

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 may 2026, 19:17 UTC

Charlas de Mercado

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 may 2026, 19:10 UTC

Charlas de Mercado

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 may 2026, 18:54 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

22 may 2026, 18:54 UTC

Charlas de Mercado

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 may 2026, 18:38 UTC

Charlas de Mercado

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 may 2026, 18:35 UTC

Adquisiciones, fusiones, absorciones

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 may 2026, 18:09 UTC

Charlas de Mercado

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 may 2026, 17:58 UTC

Charlas de Mercado

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

22 may 2026, 17:54 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

22 may 2026, 17:54 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 may 2026, 17:54 UTC

Charlas de Mercado

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

22 may 2026, 17:03 UTC

Charlas de Mercado

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

22 may 2026, 16:54 UTC

Charlas de Mercado

Crypto Spot Volumes Fall 14% in April -- Market Talk

22 may 2026, 16:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

22 may 2026, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

22 may 2026, 16:20 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

22 may 2026, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

22 may 2026, 16:16 UTC

Charlas de Mercado

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

22 may 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

22 may 2026, 15:55 UTC

Charlas de Mercado

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

22 may 2026, 15:42 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 may 2026, 15:42 UTC

Charlas de Mercado

Oil Continues as Leading Indicator for All Markets -- Market Talk

22 may 2026, 15:35 UTC

Charlas de Mercado

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Comparación entre iguales

Cambio de precio

Incyte Corp previsión

Precio Objetivo

By TipRanks

11.46% repunte

Estimación a 12 Meses

Media 108.29 USD 11.46%

Máximo 135 USD

Mínimo 75 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Incyte Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

19 ratings

Comprar

Mantener

Vender

De acuerdo con 19 analistas que ofrecen calificaciones bursátiles a para Incyte Corp Dist en los últimos 3 meses.

Sentimiento

By Acuity

47 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation